Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease

Colombel, J F, Rutgeerts, P, Malchow, H, Jacyna, M, Nielsen, O H, Rask-Madsen, J, Van Deventer, S, Ferguson, A, Desreumaux, P, Forbes, A ORCID:, Geboes, K, Melani, L and Cohard, M (2001) Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut, 49 (1). pp. 42-46. ISSN 0017-5749

Full text not available from this repository. (Request a copy)


New lesions of Crohn's disease occur early after ileal or ileocolonic resection and ileocolonic anastomosis. We performed a double blind controlled trial to evaluate the safety and tolerance of recombinant human interleukin 10 (IL-10; Tenovil) in subjects operated on for Crohn's disease. We also assessed the effect of Tenovil in preventing endoscopic recurrence 12 weeks after surgery.

Item Type: Article
Uncontrolled Keywords: adult,chemotherapy, adjuvant,colonoscopy,crohn disease,double-blind method,electrophoresis, agar gel,female,hematocrit,hemoglobins,humans,interleukin-1,interleukin-10,intestinal mucosa,male,patient compliance,recurrence,reverse transcriptase polymerase chain reaction,statistics, nonparametric,treatment outcome,tumor necrosis factor-alpha,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 06 Aug 2014 10:38
Last Modified: 20 Oct 2022 19:30
DOI: 10.1136/gut.49.1.42

Actions (login required)

View Item View Item